Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis

Manuela Colucci; Raffaella Labbadia; Marina Vivarelli; Francesca Diomedi Camassei; Francesco Emma; Luca Dello Strologo

doi:10.1007/s00467-019-04365-w

Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis

Manuela Colucci, Raffaella Labbadia, Marina Vivarelli, Francesca Diomedi Camassei, Francesco Emma, Luca Dello Strologo

Ospedale Pediatrico Bambino Gesu

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Treatment of post-transplant focal segmental glomerulosclerosis (FSGS) recurrence is still debated. The use of the fully human anti-CD20 monoclonal antibody ofatumumab has been suggested.

CASE-DIAGNOSIS/TREATMENT: Two boys with FSGS received a kidney transplantation at the age of 15 years from a deceased and a living donor. Maintenance therapy consisted of calcineurin inhibitors, antiproliferative agents, and prednisone. Early post-transplant FSGS recurrence was observed after 2 and 3 days. Rituximab infusion and plasmapheresis sessions were performed with transient clinical improvement in the first patient, and no apparent response in the second patient. Both patients were treated with two ofatumumab infusions, which induced in patient #1 a complete and stable remission for more than 12 months and in patient #2 a partial remission with a progressive reduction of proteinuria and normalization of serum protein levels.

CONCLUSIONS: Ofatumumab may be a therapeutic option for post-transplant FSGS recurrence in patients who respond poorly to rituximab.

Original language	English
Pages (from-to)	341-345
Number of pages	5
Journal	Pediatric Nephrology
Volume	35
Issue number	2
DOIs	https://doi.org/10.1007/s00467-019-04365-w
Publication status	E-pub ahead of print - 2019

Access to Document

10.1007/s00467-019-04365-w

Cite this

@article{9cf38bed31b246339d8a1d6160897603,

title = "Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis",

abstract = "BACKGROUND: Treatment of post-transplant focal segmental glomerulosclerosis (FSGS) recurrence is still debated. The use of the fully human anti-CD20 monoclonal antibody ofatumumab has been suggested.CASE-DIAGNOSIS/TREATMENT: Two boys with FSGS received a kidney transplantation at the age of 15 years from a deceased and a living donor. Maintenance therapy consisted of calcineurin inhibitors, antiproliferative agents, and prednisone. Early post-transplant FSGS recurrence was observed after 2 and 3 days. Rituximab infusion and plasmapheresis sessions were performed with transient clinical improvement in the first patient, and no apparent response in the second patient. Both patients were treated with two ofatumumab infusions, which induced in patient #1 a complete and stable remission for more than 12 months and in patient #2 a partial remission with a progressive reduction of proteinuria and normalization of serum protein levels.CONCLUSIONS: Ofatumumab may be a therapeutic option for post-transplant FSGS recurrence in patients who respond poorly to rituximab.",

author = "Manuela Colucci and Raffaella Labbadia and Marina Vivarelli and Camassei, {Francesca Diomedi} and Francesco Emma and {Dello Strologo}, Luca",

year = "2019",

doi = "10.1007/s00467-019-04365-w",

language = "English",

volume = "35",

pages = "341--345",

journal = "Pediatric Nephrology",

issn = "0931-041X",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis

AU - Colucci, Manuela

AU - Labbadia, Raffaella

AU - Vivarelli, Marina

AU - Camassei, Francesca Diomedi

AU - Emma, Francesco

AU - Dello Strologo, Luca

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Treatment of post-transplant focal segmental glomerulosclerosis (FSGS) recurrence is still debated. The use of the fully human anti-CD20 monoclonal antibody ofatumumab has been suggested.CASE-DIAGNOSIS/TREATMENT: Two boys with FSGS received a kidney transplantation at the age of 15 years from a deceased and a living donor. Maintenance therapy consisted of calcineurin inhibitors, antiproliferative agents, and prednisone. Early post-transplant FSGS recurrence was observed after 2 and 3 days. Rituximab infusion and plasmapheresis sessions were performed with transient clinical improvement in the first patient, and no apparent response in the second patient. Both patients were treated with two ofatumumab infusions, which induced in patient #1 a complete and stable remission for more than 12 months and in patient #2 a partial remission with a progressive reduction of proteinuria and normalization of serum protein levels.CONCLUSIONS: Ofatumumab may be a therapeutic option for post-transplant FSGS recurrence in patients who respond poorly to rituximab.

AB - BACKGROUND: Treatment of post-transplant focal segmental glomerulosclerosis (FSGS) recurrence is still debated. The use of the fully human anti-CD20 monoclonal antibody ofatumumab has been suggested.CASE-DIAGNOSIS/TREATMENT: Two boys with FSGS received a kidney transplantation at the age of 15 years from a deceased and a living donor. Maintenance therapy consisted of calcineurin inhibitors, antiproliferative agents, and prednisone. Early post-transplant FSGS recurrence was observed after 2 and 3 days. Rituximab infusion and plasmapheresis sessions were performed with transient clinical improvement in the first patient, and no apparent response in the second patient. Both patients were treated with two ofatumumab infusions, which induced in patient #1 a complete and stable remission for more than 12 months and in patient #2 a partial remission with a progressive reduction of proteinuria and normalization of serum protein levels.CONCLUSIONS: Ofatumumab may be a therapeutic option for post-transplant FSGS recurrence in patients who respond poorly to rituximab.

U2 - 10.1007/s00467-019-04365-w

DO - 10.1007/s00467-019-04365-w

M3 - Article

C2 - 31667616

SN - 0931-041X

VL - 35

SP - 341

EP - 345

JO - Pediatric Nephrology

JF - Pediatric Nephrology

IS - 2

ER -

Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis

Abstract

Access to Document

Fingerprint

Cite this